Ototoxicity of Artemether / Lumefantrine (Coartem) and Other Antimalarials

Overview

The purpose of the study is to evaluate the potential side-effects of artemether / lumefantrine and other antimalarials on the auditory function.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Masking: None (Open Label)

Detailed Description

Artemisinin based combination therapies (ACT) currently are the most promising treatment options for uncomplicated falciparum malaria. There have been controversial reports about possible ototoxicity of artemether / lumefantrine (Coartem®) from retrospective studies. In this investigation treatment of uncomplicated malaria with artemether / lumefantrine, quinine, where side-effects on hearing are known, or atovaquone / proguanil, where no such effects have been reported, are compared. Auditoy function is examined (Auditory Brainstem Response, Pure-tone Audiometry, Otoacustic Emissions) before treatment, after 7, 28, and, for determination of irreversibility, after 90 days.

Interventions

  • Drug: artemether/lumefantrine
  • Drug: quinine
  • Drug: atovaquone/proguanil

Participating in This Clinical Trial

Inclusion Criteria

  • Patients aged above 5 years – Uncomplicated falciparum malaria – Axillary Temperature ≥37,5°C or history of fever within the previous 24 hours – Ability to tolerate oral therapy – Informed consent by the patient or by parent/guardian for children – Residence in study area Exclusion Criteria:

  • Known or suspected hearing deficits – Adequate anti-malarial treatment within the previous 7 days – Mixed infection – Danger signs and signs of severe malaria as defined by the WHO – Presence of severe underlying disease (cardiac, renal, hepatic diseases, malnutrition, known HIV infection) – Concomitant disease masking assessment of response – History of allergy or intolerance against study medications – Pregnancy

Gender Eligibility: All

Minimum Age: 5 Years

Maximum Age: N/A

Investigator Details

  • Lead Sponsor
    • Jimma University
  • Collaborator
    • Ludwig-Maximilians – University of Munich
  • Overall Official(s)
    • Nebreed Fesseaha, MD, Dean, Study Chair, Facuty of Medical Sciences Jimma University

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.